Finding the best dose of anti-lymphocyte globulin for kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests different doses of an anti-rejection drug (anti-lymphocyte globulin) in people receiving their first kidney transplant. It aims to find the safest and most effective dose for patients with a lower risk of rejecting the new kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are getting your very first kidney transplant.
- You can use effective birth control if you or your partner could become pregnant.
- You are covered by the French social security system.
- You do not have a high risk of rejecting the kidney (like having antibodies against the donor).
- You have not had a previous organ transplant or certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
This trial tests whether giving albumin (a protein in your blood) after a liver transplant can help prevent or reduce kidney damage. It is for adults receiving their first liver-only transplant from a deceased donor.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study follows older people who received a kidney transplant and are taking a specific immune-suppressing medicine plan (Advagraf/tacrolimus once daily plus mycophenolate and steroids). It may help researchers understand outcomes in real-world patients who match these medication and immune-risk criteria.
This study looks at how well a new blood test works to monitor kidney health after a transplant. It might help doctors catch problems early without needing a biopsy.
Hear when a new Renal Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.